The agreement encompasses development and commercial milestones for the products, which could amount to up to $180m.

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

Alvotech (ALVO) stock is in focus as the company partners with Advanz Pharma to market three additional biosimilars across ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to ...

Shanghai, China, May 26, 2025 (GLOBE NEWSWIRE) -- Friso, the Dutch infant nutrition brand with a longstanding commitment to ...